CH624123A5 - - Google Patents
Download PDFInfo
- Publication number
- CH624123A5 CH624123A5 CH1094877A CH1094877A CH624123A5 CH 624123 A5 CH624123 A5 CH 624123A5 CH 1094877 A CH1094877 A CH 1094877A CH 1094877 A CH1094877 A CH 1094877A CH 624123 A5 CH624123 A5 CH 624123A5
- Authority
- CH
- Switzerland
- Prior art keywords
- formula
- acid
- herpes
- phosphonate
- och
- Prior art date
Links
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 29
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 17
- 150000001875 compounds Chemical class 0.000 claims description 12
- 229960000583 acetic acid Drugs 0.000 claims description 11
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 claims description 10
- 241001529453 unidentified herpesvirus Species 0.000 claims description 10
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 7
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 5
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 5
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 238000002360 preparation method Methods 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 3
- 239000011707 mineral Substances 0.000 claims description 3
- 150000003839 salts Chemical class 0.000 claims description 3
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 2
- 150000001412 amines Chemical class 0.000 claims description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims 2
- 208000001688 Herpes Genitalis Diseases 0.000 claims 1
- 206010062639 Herpes dermatitis Diseases 0.000 claims 1
- 208000000903 Herpes simplex encephalitis Diseases 0.000 claims 1
- 208000037018 Herpes simplex virus encephalitis Diseases 0.000 claims 1
- 208000029433 Herpesviridae infectious disease Diseases 0.000 claims 1
- 208000005100 Herpetic Keratitis Diseases 0.000 claims 1
- 206010073938 Ophthalmic herpes simplex Diseases 0.000 claims 1
- 201000004946 genital herpes Diseases 0.000 claims 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims 1
- 239000010931 gold Substances 0.000 claims 1
- 229910052737 gold Inorganic materials 0.000 claims 1
- 201000010884 herpes simplex virus keratitis Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 14
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 13
- 239000002253 acid Substances 0.000 description 8
- -1 alkali metal salts Chemical class 0.000 description 8
- 238000004458 analytical method Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- AKVIWWJLBFWFLM-UHFFFAOYSA-N (2-amino-2-oxoethyl)phosphonic acid Chemical compound NC(=O)CP(O)(O)=O AKVIWWJLBFWFLM-UHFFFAOYSA-N 0.000 description 6
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 239000000706 filtrate Substances 0.000 description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- QOJLTIJRCYTUDQ-UHFFFAOYSA-N 2-dimethoxyphosphorylacetic acid Chemical compound COP(=O)(OC)CC(O)=O QOJLTIJRCYTUDQ-UHFFFAOYSA-N 0.000 description 5
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 5
- XSHUKGCVDBQESI-UHFFFAOYSA-N [2-(butylamino)-2-oxoethyl]phosphonic acid Chemical compound CCCCNC(=O)CP(O)(O)=O XSHUKGCVDBQESI-UHFFFAOYSA-N 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- XUYJLQHKOGNDPB-UHFFFAOYSA-N phosphonoacetic acid Chemical compound OC(=O)CP(O)(O)=O XUYJLQHKOGNDPB-UHFFFAOYSA-N 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- FZDONQZZKFPVQO-UHFFFAOYSA-N [2-(diethylamino)-2-oxoethyl]phosphonic acid Chemical compound CCN(CC)C(=O)CP(O)(O)=O FZDONQZZKFPVQO-UHFFFAOYSA-N 0.000 description 2
- WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- YLFBFPXKTIQSSY-UHFFFAOYSA-N dimethoxy(oxo)phosphanium Chemical compound CO[P+](=O)OC YLFBFPXKTIQSSY-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- PCDQPRRSZKQHHS-UHFFFAOYSA-N Cytidine 5'-triphosphate Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-WFVLMXAXSA-N DEAE-cellulose Chemical compound OC1C(O)C(O)C(CO)O[C@H]1O[C@@H]1C(CO)OC(O)C(O)C1O GUBGYTABKSRVRQ-WFVLMXAXSA-N 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 241001197891 Emydid herpesvirus Species 0.000 description 1
- XKMLYUALXHKNFT-UUOKFMHZSA-N Guanosine-5'-triphosphate Chemical compound C1=2NC(N)=NC(=O)C=2N=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O XKMLYUALXHKNFT-UUOKFMHZSA-N 0.000 description 1
- 206010019973 Herpes virus infection Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 238000000585 Mann–Whitney U test Methods 0.000 description 1
- RZCIEJXAILMSQK-JXOAFFINSA-N TTP Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 RZCIEJXAILMSQK-JXOAFFINSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- MKRNGUDVOWSJDL-UHFFFAOYSA-N [2-(octylamino)-2-oxoethyl]phosphonic acid Chemical compound CCCCCCCCNC(=O)CP(O)(O)=O MKRNGUDVOWSJDL-UHFFFAOYSA-N 0.000 description 1
- MNZMECMQTYGSOI-UHFFFAOYSA-N acetic acid;hydron;bromide Chemical compound Br.CC(O)=O MNZMECMQTYGSOI-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 229960001456 adenosine triphosphate Drugs 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 125000005115 alkyl carbamoyl group Chemical group 0.000 description 1
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
- 229960003805 amantadine Drugs 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- FOCAUTSVDIKZOP-UHFFFAOYSA-N chloroacetic acid Chemical compound OC(=O)CCl FOCAUTSVDIKZOP-UHFFFAOYSA-N 0.000 description 1
- 229940106681 chloroacetic acid Drugs 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- PCDQPRRSZKQHHS-ZAKLUEHWSA-N cytidine-5'-triphosphate Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO[P@](O)(=O)O[P@@](O)(=O)OP(O)(O)=O)O1 PCDQPRRSZKQHHS-ZAKLUEHWSA-N 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- JUVJQIPDVWOVNP-UHFFFAOYSA-N hexylurea Chemical compound CCCCCCNC(N)=O JUVJQIPDVWOVNP-UHFFFAOYSA-N 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- NGOOTARIWNEPFD-UHFFFAOYSA-N methoxy-[2-oxo-2-(propylamino)ethyl]phosphinic acid Chemical compound CCCNC(=O)CP(O)(=O)OC NGOOTARIWNEPFD-UHFFFAOYSA-N 0.000 description 1
- OXQMIXBVXHWDPX-UHFFFAOYSA-N n,n,2-trimethylpropan-2-amine Chemical compound CN(C)C(C)(C)C OXQMIXBVXHWDPX-UHFFFAOYSA-N 0.000 description 1
- 229940080469 phosphocellulose Drugs 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- XKMLYUALXHKNFT-UHFFFAOYSA-N rGTP Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O XKMLYUALXHKNFT-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US05/721,611 US4087522A (en) | 1976-09-08 | 1976-09-08 | Amides of phosphonoacetic acid for treating herpes simplex virus type 1 and 2 infections |
Publications (1)
Publication Number | Publication Date |
---|---|
CH624123A5 true CH624123A5 (nl) | 1981-07-15 |
Family
ID=24898614
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CH1094877A CH624123A5 (nl) | 1976-09-08 | 1977-09-07 |
Country Status (9)
Country | Link |
---|---|
US (2) | US4087522A (nl) |
JP (1) | JPS5334726A (nl) |
AU (1) | AU511458B2 (nl) |
CA (1) | CA1108131A (nl) |
CH (1) | CH624123A5 (nl) |
DE (1) | DE2740354A1 (nl) |
FR (1) | FR2364224A1 (nl) |
GB (1) | GB1565025A (nl) |
NL (1) | NL7709639A (nl) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2926799A1 (de) * | 1979-07-03 | 1981-01-15 | Bayer Ag | Phosphonoameisensaeurehydrazide, verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
US4272528A (en) * | 1980-08-14 | 1981-06-09 | Abbott Laboratories | Phosphonoacetyl aminoacids |
US4525289A (en) * | 1981-12-29 | 1985-06-25 | The Procter & Gamble Company | Alpha-phosphono lauramide lubricant additives |
CA2336143A1 (en) | 1998-07-15 | 2000-01-27 | Hassan Jomaa | Aminoalkylphosphonic acid derivatives and their use in treating infections |
US7994996B2 (en) * | 1999-11-18 | 2011-08-09 | TK Holding Inc., Electronics | Multi-beam antenna |
US11548893B2 (en) | 2017-07-15 | 2023-01-10 | Arisan Therapeutics Inc. | Enantiomerically pure adamantane carboxamides for the treatment of filovirus infection |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3767795A (en) * | 1971-02-25 | 1973-10-23 | Abbott Lab | Method for combating certain virus infection |
DE2318254A1 (de) * | 1972-05-17 | 1973-12-06 | Merck & Co Inc | Wachstumshemmer und herbicide |
US4063923A (en) * | 1973-07-23 | 1977-12-20 | E. I. Du Pont De Nemours And Company | Carbamoylphosphonic acid brush control agents |
DE2447726A1 (de) * | 1974-10-07 | 1976-04-08 | Hoechst Ag | Schwerentflammbare kunststoffe |
DE2511185A1 (de) * | 1975-03-14 | 1976-09-23 | Hoechst Ag | Schwerentflammbare kunststoffe |
-
1976
- 1976-09-08 US US05/721,611 patent/US4087522A/en not_active Expired - Lifetime
-
1977
- 1977-08-16 CA CA284,784A patent/CA1108131A/en not_active Expired
- 1977-08-22 AU AU28096/77A patent/AU511458B2/en not_active Expired
- 1977-08-30 JP JP10329777A patent/JPS5334726A/ja active Pending
- 1977-09-01 NL NL7709639A patent/NL7709639A/nl not_active Application Discontinuation
- 1977-09-06 FR FR7726982A patent/FR2364224A1/fr active Granted
- 1977-09-07 GB GB37397/77A patent/GB1565025A/en not_active Expired
- 1977-09-07 CH CH1094877A patent/CH624123A5/fr not_active IP Right Cessation
- 1977-09-07 DE DE19772740354 patent/DE2740354A1/de not_active Withdrawn
-
1978
- 1978-04-24 US US05/899,766 patent/US4138432A/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US4138432A (en) | 1979-02-06 |
JPS5334726A (en) | 1978-03-31 |
GB1565025A (en) | 1980-04-16 |
AU511458B2 (en) | 1980-08-21 |
US4087522A (en) | 1978-05-02 |
DE2740354A1 (de) | 1978-03-09 |
AU2809677A (en) | 1979-03-01 |
CA1108131A (en) | 1981-09-01 |
FR2364224B1 (nl) | 1981-03-06 |
FR2364224A1 (fr) | 1978-04-07 |
NL7709639A (nl) | 1978-03-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE69332220T2 (de) | Lösliche analoga von probucol | |
CA1265517A (fr) | DERIVES DE L'ACIDE .alpha.-[OXO-2 HEXAHYDRO-2,4,5,6,7, 7A THIENO (3,2-C) PYRIDYL-5] PHENYL ACETIQUE, LEUR PROCEDE DE PREPARATION ET LEUR APPLICATION THERAPEUTIQUE | |
FR2530247A1 (fr) | Nouveaux derives de la thieno (3, 2-c) pyridine, leur procede de preparation et leur application therapeutique | |
FR2487829A2 (fr) | Nouveaux imino acides substitues, leurs procedes de preparation et leur emploi comme inhibiteur d'enzyme | |
EP0046707A1 (fr) | Dérivés de l'acide amino-4 butyrique et les médicaments, actifs notamment sur le système nerveux central, en contenant | |
CH624123A5 (nl) | ||
EP0262053A2 (fr) | Nouveaux dérivés d'amino-acides, leur procédé de préparation et compositions pharmaceutiques les contenant | |
FR2672213A1 (fr) | Utilisation de derives 4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridiniques comme capteurs de radicaux libres. | |
CH625214A5 (nl) | ||
LU83307A1 (fr) | Derives d'adenosine a activite anti-inflammatoire et analgesique,ainsi que des compositions therapeutiques contenant ces derives comme principe actif | |
DE2801478C2 (nl) | ||
FR2597865A1 (fr) | Nouveaux derives d'un acide benzyl alkyl carboxylique substitue par un radical 4-pyridinyl aminocarbonyle, leur procede de preparation, les nouveaux intermediaires obtenus, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant | |
CH632999A5 (fr) | (2-thio)urees 1,3-disubstituees. | |
FR2470110A1 (fr) | Derives de la decrapenylamine, leurs sels acides d'addition et composition pharmaceutique renfermant ces produits | |
LU85780A1 (fr) | Nouveaux esters enoliques precurseurs de medicaments et composition pharmaceutique les contenant | |
US4500531A (en) | Therapeutical use of (1-cinnamoyl or 1-phenethylcarbonyl) piperazine derivatives | |
JPH0560478B2 (nl) | ||
LU84062A1 (fr) | Esters de mercaptoacyl-carnitines,procede pour leur preparation et leurs utilisations therapeutiques,notamment dans le traitement des intoxications et des brulures et en tant qu'agents mucolytiques | |
EP0203450B1 (de) | Neue Derivate bicyclischer Aminosäuren, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung | |
EP0244318B1 (fr) | Nouveaux dérivés de la N-[(triméthoxy-2,4,6-benzoyl)-3 propyl] pipéridine, leurs procédés de préparation et leur application en thérapeutique | |
DE3222779C2 (nl) | ||
FR2534588A2 (fr) | Nouvelles oximes derivees de l'erythromycine, leur procede de preparation et leur application comme medicaments | |
JPS63502432A (ja) | アシル化シアナミド組成物 | |
FR2584070A1 (fr) | Nouveaux derives de l'hydroxy alkoxy 4-phenyl propyl indole, leurs sels, procede et intermediaires de preparation, application a titre de medicaments et compositions les renfermant. | |
DE69411747T2 (de) | Phosphinsäure-derivate mit anti-hyperglyzemie und/oder anti-fettsucht wirkung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PL | Patent ceased |